Bryan, Garnier & Co Makes Significant Move into the Nordics with the Acquisition of Beringer Finance
Today, Bryan, Garnier & Co announced the acquisition of Beringer Finance and the expansion of its partnership. Beringer Finance is a premier, Nordic-focused boutique investment bank with offices in Stockholm, Oslo, Reykjavik and Palo Alto. Throughout the past 10 years, Beringer Finance has advised on over 140 transactions, building a strong track record in the TMT, IT Services, and Fintech markets. The closing is subject to pending regulatory approvals and other customary closing conditions.
Olivier Garnier, Co-founder and Managing Partner of Bryan, Garnier & Co comments: “Bryan, Garnier & Co is an independent partnership that combines highly experienced, entrepreneur-minded investment banking professionals with the services and expertise of a top-tier investment bank. The culture of excellence at Beringer Finance and our shared ambition to expand will be a strong driver to accelerate Bryan, Garnier & Co’s development in the region, across our business lines and industry sectors. We are delighted to welcome Adalsteinn Johannsson and his team to lead this effort”.
“The Nordics is one of the main European Technology and Life Sciences hubs where we have longstanding client relationships” comments Greg Revenu, Managing Partner of Bryan, Garnier & Co. “This combination not only creates an exciting opportunity for the firm and its teams, but also a unique capacity to support the growth of our clients: it propels our Technology coverage to the next level, while opening a new challenge to our leading European healthcare franchise.”
“We are excited to be joining forces with Bryan, Garnier & Co” explains Adalsteinn Johannsson, CEO at Beringer Finance “Its full-service capacities combining investment banking and capital markets services provides us with the scale and resources to accelerate our growth. Bryan, Garnier & Co’s entrepreneurial DNA is a perfect match for the strong culture and unique approach we have built at Beringer. We very much look forward writing this journey together with this outstanding team.”
Beringer Finance will be operating under the Bryan, Garnier & Co brand with CEO Adalsteinn Johannsson joining Bryan, Garnier & Co as a partner focused on International M&A, with Beringer’s Tor Berthelius as a partner to lead the Nordic operations. Beringer’s 27 technology-focused bankers will be fully integrated with Bryan, Garnier & Co’s existing investment banking professionals, across its London, Paris, Munich, Stockholm, Oslo, Reykjavik, New York and Palo Alto offices. With a European technology group of more than 80 professionals, Bryan, Garnier & Co will benefit from an unmatched position in the European technology investment banking landscape.
RECENT ACHIEVEMENTS
Over the past 24 months, Bryan, Garnier & Co and Beringer Finance have led more than 85 transactions, including backing three of the most disruptive unicorns of 2018:
- 47 international public and private M&A deals representing an aggregate value of approximately $2.4 billion, many of which involved tier one private equity investors and publicly-listed trade buyers. Recent deals include the sale of Sword Apak to Sopra Banking Software, the sale of Symetis to Boston Scientific for $435m, the sale of Dimelo to RingCentral, the sale of Prima Solutions to the Carlyle Group, the 30% sale of Advania to VIA equity and PFA, and the sale of Universum to Axel Springer company StepStone.
- 25 growth capital private placements and PIPEs representing an aggregated amount raised of some $550 million, for companies such as blockchain unicorn Bitfury ($80m), biotech unicorn Moderna ($80m), Tado° ($50m), Highlife ($37m), Devialet ($210m), and BraBank ($35m).
- 15 IPOs and public offerings on Nasdaq, NYSE, Euronext, and other major exchanges for an aggregated amount of more than $1.4 billion, including four deals led or co-led on Nasdaq or NYSE. Recent transactions include: representation of cannabis unicorn Canopy Growth ($450m, TMX, NYSE), Medartis ($138m, Swiss Exchange), Materialise ($52m, Nasdaq), Medigene ($56m, Deutsche Börse Group), Celyad ($53m, Nasdaq, Euronext) and Genfit ($155.4m, Nasdaq).
About Beringer Finance (www.beringerfinance.com)
Beringer Finance is a technology focused boutique investment bank with offices in Stockholm, Oslo, Reykjavik and Palo Alto. Tracing its roots back over 100 years, Beringer is continuously driven by the ambition to help companies and entrepreneurs strategically develop and grow their businesses while realizing their dreams and their aspirations.
Their expertise and market leadership have seen them advise top-tier clients on over 140 transactions in the past 10 years. Despite calling the Nordics its home, Beringer works across all continents and focuses on M&A and private placements after selling its Fondsfinans brokerage business in 2018.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorised and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich and New York. The firm is a member of the London Stock Exchange and Euronext.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190417005049/en/
Contact information
Press contact: Profile!
Caroline MATUSZEWSKI - Leslie
BOUTIN- SOSSAH
+ 33 1 56 26 72 32 – 33
cmatuszewski@agence-profile.com
lboutin@agence-profile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom